Collagen-alpha-1(VI)-chain Degradome Foundation Atlas

It is particularly important in the extracellular matrix surrounding muscle and other tissues, where it participates in interactions between cells and the surrounding matrix. COL6A1 is also directly relevant to human disease, with pathogenic variants associated with collagen VI-related myopathies, including <b>Bethlem muscular dystrophy and Ullrich congenital muscular dystrophy</b>. Characterizing the proteolytic fragment landscape of COL6A1 may therefore provide valuable insights into extracellular matrix remodeling, muscle pathology, connective-tissue biology, tissue injury, and the development of peptide-based biomarkers.</p><h3 dir="ltr">Key Features of the Proteomics Dataset</h3><p dir="ltr">Using predicted enzymatic and chemical cleavage sites, the atlas systematically generates and annotates possible COL6A1 peptide fragments.

Each fragment is characterized using physicochemical features relevant to mass spectrometry, proteomics, and computational peptide analysis.</p><p dir="ltr"><b>Mass Spectrometry and Peptide Metrics:</b></p><ul><li>Molecular weight</li><li>Mass-to-charge ratio (m/z)</li><li>Net charge</li><li>Isoelectric point (pI)</li></ul><p dir="ltr"><b>Biochemical and Biophysical Features:</b></p><ul><li>Hydrophobicity</li><li>Boman index</li><li>Instability index</li><li>Aliphatic index</li></ul><p dir="ltr">Together, these annotations provide a feature-rich computational reference for exploring the detectability, physicochemical behaviour, and potential analytical relevance of COL6A1-derived peptides.</p><h3 dir="ltr">Applications in Biomarker Discovery and Biomedical Research</h3><p dir="ltr">The <b>Collagen Alpha-1(VI) Chain Degradome Foundation Atlas</b> can support a broad range of experimental and computational applications, including:</p><ul><li><b>Targeted Proteomics:</b> Identification and prioritization of candidate COL6A1-derived peptides for mass-spectrometry assays.</li><li><b>Biomarker Discovery:</b> Exploration of collagen-derived peptide candidates associated with extracellular matrix remodeling, muscle injury, muscular dystrophy, connective-tissue disorders, fibrosis, and tissue degeneration.</li><li><b>Discovery Proteomics:</b> Interpretation and annotation of COL6A1-derived signals detected in mass-spectrometry datasets and biological fluids.</li><li><b>Degradomics:</b> Investigation of potential proteolytic processing patterns, extracellular matrix protease activity, and collagen-derived fragment populations.</li><li><b>Clinical Proteomics:</b> Computational exploration of Type VI collagen turnover in physiological conditions and disease-associated extracellular matrix remodeling.</li><li><b>Muscle and Neuromuscular Research:</b> Investigation of COL6A1 processing in skeletal muscle biology, muscle degeneration, muscular dystrophies, and extracellular matrix abnormalities.</li><li><b>Connective-Tissue Research:</b> Exploration of COL6A1-derived fragments in disorders affecting collagen VI structure, extracellular matrix organization, and tissue integrity.</li><li><b>Computational Biology:</b> Generation of reference features for peptide-level modelling, degradome analysis, and machine-learning applications.</li><li><b>Assay Development:</b> Prioritization of candidate COL6A1 peptides for future experimental validation.</li></ul><h3 dir="ltr">Data Inclusion and Reproducibility</h3><p dir="ltr">The atlas provides a systematic computational representation of the <b>wild-type COL6A1 degradome</b>, including the complete set of theoretically generated contiguous peptide fragments and their calculated physicochemical properties.</p><p dir="ltr">Importantly, this Foundation Atlas represents a <b>theoretical fragment space rather than a catalogue of experimentally confirmed collagen peptides</b>.

Experimental proteomic and mass-spectrometry studies will be required to establish which predicted fragments are generated and detectable under physiological or disease-associated conditions.</p><p dir="ltr">Future releases will expand the resource through the incorporation of <b>disease-associated COL6A1 variants, post-translational and extracellular matrix modifications, experimentally validated cleavage products, and complementary experimental proteomics data</b>, progressively extending the atlas from a theoretical reference framework toward an experimentally informed representation of the COL6A1 degradome.</p>